drugset / Trial / NCT06774885

ROLE OF FOLIC ACID IN THE MANAGEMENT OF ADJUVANT ENDOCRINE THERAPY-INDUCED HOT FLASHES IN BREAST CANCER PATIENTS

NCT06774885

Phase 3 Not yet recruiting 120 enrolled Future University in Egypt
RandomizedParallel-groupSingle-blindTreatment

Summary

The study's objective is to investigate the role of folic acid administration in the management of hot flashes associated with adjuvant endocrine therapy in patients with breast cancer.

Timeline

Start
2025-02-09
Primary completion
2025-08
Completion
2025-08

Drugs

EvaluationDrugModalityDoseRoute
Subject folic acid Other / unclassified 1 mg Oral
Subject folic acid Other / unclassified 5 mg Oral

Indications

No indication recorded.